G&A at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s G&A?
- Praxis Precision Medicines, Inc. (PRAX) reported G&A of $27.87M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s G&A changed year-over-year?
- Praxis Precision Medicines, Inc.'s G&A increased by 100.2% year-over-year, from $13.92M to $27.87M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s G&A?
- Over 4 years (2021 to 2025), Praxis Precision Medicines, Inc.'s G&A has grown at a 5.8% compound annual growth rate (CAGR), from $47.08M to $59.08M.
- What does G&A mean?
- The overhead costs required to run the day-to-day business operations.
- How do you interpret G&A?
- An increase relative to revenue may indicate operational inefficiency or excessive corporate overhead.
- How does G&A compare across companies?
- Typically benchmarked as a percentage of total operating expenses to assess administrative leaness.